跳至主要内容
临床试验/NCT00132717
NCT00132717已完成3 期

An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination Tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary Event

Organon and Co0 个研究点目标入组 450 人开始时间: 2005年1月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
450
主要终点
Evaluate the effectiveness of MK0653A compared to doubling the statin dose as shown by the low-density lipoprotein cholesterol (LDL-C) values achieved after 12 weeks of treatment

研究概览

简要总结

The purpose of this study is to investigate the effect of an investigational cholesterol-lowering drug in patients who are currently taking an approved medication for hypercholesterolemia (high cholesterol levels) and have been hospitalized for a heart problem.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients greater than 18 years old, who were admitted to a hospital for an investigation of a heart problem and are currently receiving an approved medication to lower cholesterol

排除标准

  • Patients who have congestive heart failure (CHF), uncontrolled high blood pressure, poorly controlled blood sugar, impaired kidney function, or HIV.

结局指标

主要结局

Evaluate the effectiveness of MK0653A compared to doubling the statin dose as shown by the low-density lipoprotein cholesterol (LDL-C) values achieved after 12 weeks of treatment

时间窗: After 12 weeks of treatment

次要结局

  • To determine the effect of MK0653A compared to doubling the statin dose on total cholesterol (TC) after 12 weeks(After 12 weeks of treatment)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验